{"id":67809,"date":"2026-06-09T23:25:51","date_gmt":"2026-06-09T15:25:51","guid":{"rendered":"https:\/\/flcube.com\/?p=67809"},"modified":"2026-06-09T23:25:53","modified_gmt":"2026-06-09T15:25:53","slug":"shandong-buchang-pharmaceuticals-partners-with-vietnamese-mkt-for-exclusive-adalimumab-biosimilar-distribution-in-vietnam","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=67809","title":{"rendered":"Shandong Buchang Pharmaceuticals Partners with Vietnamese MKT for Exclusive Adalimumab Biosimilar Distribution in Vietnam"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Shandong Buchang Pharmaceuticals Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/603858:SHA\">SHA: 603858<\/a>) announced today plans to sign a <strong>&#8220;Distribution, Marketing Services and Agency Agreement&#8221;<\/strong> with Vietnamese company <strong>MKT<\/strong>, granting MKT <strong>exclusive marketing and distribution rights<\/strong> for its <strong>adalimumab biosimilar<\/strong> within the territory of <strong>Vietnam<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-partnership-structure\" class=\"wp-block-heading\">Partnership Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Originator Company<\/strong><\/td><td>Shandong Buchang Pharmaceuticals Co., Ltd. (SHA: 603858)<\/td><\/tr><tr><td><strong>Distribution Partner<\/strong><\/td><td>MKT (Vietnam)<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Vietnam (exclusive rights)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Adalimumab biosimilar (referencing AbbVie&#8217;s Humira)<\/td><\/tr><tr><td><strong>Agreement Type<\/strong><\/td><td>Distribution, Marketing Services and Agency Agreement<\/td><\/tr><tr><td><strong>Regulatory Status<\/strong><\/td><td>Marketing application submitted and accepted for review in China<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-product-profile\" class=\"wp-block-heading\">Product Profile<\/h2>\n\n\n\n<h3 id=\"h-adalimumab-biosimilar-characteristics\" class=\"wp-block-heading\">Adalimumab Biosimilar Characteristics<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Reference Product<\/strong>: AbbVie&#8217;s Humira (adalimumab)<\/li>\n\n\n\n<li><strong>Development Category<\/strong>: Category 3.3 for therapeutic biological products (China classification)<\/li>\n\n\n\n<li><strong>Indications<\/strong>: Rheumatoid arthritis, ankylosing spondylitis, psoriasis, Crohn&#8217;s disease, uveitis, polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis, and pediatric Crohn&#8217;s disease<\/li>\n\n\n\n<li><strong>Biosimilar Status<\/strong>: Developed through comprehensive comparability studies to reference product<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-rationale\" class=\"wp-block-heading\">Strategic Rationale<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Entry Strategy<\/strong>: Leverages local partner expertise for efficient Vietnam market penetration<\/li>\n\n\n\n<li><strong>Biosimilar Opportunity<\/strong>: Addresses growing demand for affordable biologic alternatives in Southeast Asia<\/li>\n\n\n\n<li><strong>Regulatory Alignment<\/strong>: Builds on Chinese regulatory progress to support international expansion<\/li>\n\n\n\n<li><strong>Commercial Infrastructure<\/strong>: Utilizes MKT&#8217;s established distribution network and market knowledge<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-context\" class=\"wp-block-heading\">Market Context<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Vietnam Biologics Market<\/strong>: Rapidly growing segment with increasing government support for biosimilars<\/li>\n\n\n\n<li><strong>Adalimumab Market Size<\/strong>: Global adalimumab market valued at USD 18.4 billion in 2025 despite biosimilar competition<\/li>\n\n\n\n<li><strong>Southeast Asia Opportunity<\/strong>: Limited biosimilar availability creates significant pricing and access advantages<\/li>\n\n\n\n<li><strong>Regulatory Pathway<\/strong>: Vietnam&#8217;s biosimilar approval framework increasingly aligned with international standards<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-competitive-landscape\" class=\"wp-block-heading\">Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global Biosimilar Competition<\/strong>: Multiple adalimumab biosimilars approved in major markets including EU, US, and China<\/li>\n\n\n\n<li><strong>Local Manufacturing Advantage<\/strong>: Potential for cost-effective production supporting competitive pricing<\/li>\n\n\n\n<li><strong>First-Mover Potential<\/strong>: Early entry into Vietnam&#8217;s adalimumab biosimilar market<\/li>\n\n\n\n<li><strong>Portfolio Diversification<\/strong>: Expands Buchang&#8217;s international presence beyond traditional Chinese medicine products<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-forward-looking-statements\" class=\"wp-block-heading\">Forward-Looking Statements<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">This brief contains forward-looking statements regarding strategic partnerships, regulatory approvals, market opportunities, and commercial expectations. Actual results may differ due to risks including regulatory decisions, competitive dynamics, market adoption challenges, and execution risks in international business development.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/603858_20260609_L7ZU.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 603858_20260609_L7ZU.\"><\/object><a id=\"wp-block-file--media-83879b58-9dd3-4c61-937f-6ae1288c6dea\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/603858_20260609_L7ZU.pdf\">603858_20260609_L7ZU<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/603858_20260609_L7ZU.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-83879b58-9dd3-4c61-937f-6ae1288c6dea\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Shandong Buchang Pharmaceuticals Co., Ltd. (SHA: 603858) announced today plans to sign a &#8220;Distribution, Marketing&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10,11],"tags":[43,280,1103],"class_list":["post-67809","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","category-drug","tag-biosimilars","tag-buchang-pharmaceuticals","tag-sha-603858"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Shandong Buchang Pharmaceuticals Partners with Vietnamese MKT for Exclusive Adalimumab Biosimilar Distribution in Vietnam - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shandong Buchang Pharmaceuticals Co., Ltd. (SHA: 603858) announced today plans to sign a &quot;Distribution, Marketing Services and Agency Agreement&quot; with Vietnamese company MKT, granting MKT exclusive marketing and distribution rights for its adalimumab biosimilar within the territory of Vietnam.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=67809\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shandong Buchang Pharmaceuticals Partners with Vietnamese MKT for Exclusive Adalimumab Biosimilar Distribution in Vietnam\" \/>\n<meta property=\"og:description\" content=\"Shandong Buchang Pharmaceuticals Co., Ltd. (SHA: 603858) announced today plans to sign a &quot;Distribution, Marketing Services and Agency Agreement&quot; with Vietnamese company MKT, granting MKT exclusive marketing and distribution rights for its adalimumab biosimilar within the territory of Vietnam.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=67809\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-09T15:25:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-09T15:25:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67809#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67809\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Shandong Buchang Pharmaceuticals Partners with Vietnamese MKT for Exclusive Adalimumab Biosimilar Distribution in Vietnam\",\"datePublished\":\"2026-06-09T15:25:51+00:00\",\"dateModified\":\"2026-06-09T15:25:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67809\"},\"wordCount\":345,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Biosimilars\",\"Buchang Pharmaceuticals\",\"SHA: 603858\"],\"articleSection\":[\"Company\",\"Deals\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67809#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67809\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=67809\",\"name\":\"Shandong Buchang Pharmaceuticals Partners with Vietnamese MKT for Exclusive Adalimumab Biosimilar Distribution in Vietnam - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-09T15:25:51+00:00\",\"dateModified\":\"2026-06-09T15:25:53+00:00\",\"description\":\"Shandong Buchang Pharmaceuticals Co., Ltd. (SHA: 603858) announced today plans to sign a \\\"Distribution, Marketing Services and Agency Agreement\\\" with Vietnamese company MKT, granting MKT exclusive marketing and distribution rights for its adalimumab biosimilar within the territory of Vietnam.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67809#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67809\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67809#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shandong Buchang Pharmaceuticals Partners with Vietnamese MKT for Exclusive Adalimumab Biosimilar Distribution in Vietnam\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Shandong Buchang Pharmaceuticals Partners with Vietnamese MKT for Exclusive Adalimumab Biosimilar Distribution in Vietnam - Insight, China&#039;s Pharmaceutical Industry","description":"Shandong Buchang Pharmaceuticals Co., Ltd. (SHA: 603858) announced today plans to sign a \"Distribution, Marketing Services and Agency Agreement\" with Vietnamese company MKT, granting MKT exclusive marketing and distribution rights for its adalimumab biosimilar within the territory of Vietnam.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=67809","og_locale":"en_US","og_type":"article","og_title":"Shandong Buchang Pharmaceuticals Partners with Vietnamese MKT for Exclusive Adalimumab Biosimilar Distribution in Vietnam","og_description":"Shandong Buchang Pharmaceuticals Co., Ltd. (SHA: 603858) announced today plans to sign a \"Distribution, Marketing Services and Agency Agreement\" with Vietnamese company MKT, granting MKT exclusive marketing and distribution rights for its adalimumab biosimilar within the territory of Vietnam.","og_url":"https:\/\/flcube.com\/?p=67809","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-09T15:25:51+00:00","article_modified_time":"2026-06-09T15:25:53+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=67809#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=67809"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Shandong Buchang Pharmaceuticals Partners with Vietnamese MKT for Exclusive Adalimumab Biosimilar Distribution in Vietnam","datePublished":"2026-06-09T15:25:51+00:00","dateModified":"2026-06-09T15:25:53+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=67809"},"wordCount":345,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Biosimilars","Buchang Pharmaceuticals","SHA: 603858"],"articleSection":["Company","Deals","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=67809#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=67809","url":"https:\/\/flcube.com\/?p=67809","name":"Shandong Buchang Pharmaceuticals Partners with Vietnamese MKT for Exclusive Adalimumab Biosimilar Distribution in Vietnam - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-09T15:25:51+00:00","dateModified":"2026-06-09T15:25:53+00:00","description":"Shandong Buchang Pharmaceuticals Co., Ltd. (SHA: 603858) announced today plans to sign a \"Distribution, Marketing Services and Agency Agreement\" with Vietnamese company MKT, granting MKT exclusive marketing and distribution rights for its adalimumab biosimilar within the territory of Vietnam.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=67809#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=67809"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=67809#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Shandong Buchang Pharmaceuticals Partners with Vietnamese MKT for Exclusive Adalimumab Biosimilar Distribution in Vietnam"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67809","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=67809"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67809\/revisions"}],"predecessor-version":[{"id":67811,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67809\/revisions\/67811"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=67809"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=67809"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=67809"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}